Trimerbody

LeadArtis news image

About the cover: Model of an asymmetric bispecific scFv-based N/C-trimerbody. The scFv-domains with the same specificity are colored in blue or green, and the trimerization region is colored in red. Visit Landes Bioscience Issue online 

LeadArtis is an early stage biotechnology company based in Madrid (Spain) that develops targeted drugs based on its proprietary Trimerbody® protein engineering platform. 

Trimerbody® is an alternative antibody format that employs specific collagen trimerization domains and optimized peptide connectors to provide advantages over conventional antibodies including simultaneous multiple targeting (up to six per molecule), reduced size, higher avidity for targets, and a variety of effector possibilities such as immune system modulation, receptor modulation, soluble factor neutralization, payload delivery etc. Our key therapeutic areas for pipeline development are oncology and inflammatory/autoimmunity.

Additionally, we offer our Trimerbody® platform to partners interested in developing targeted drugs benefiting from the Trimerbody® format which offers promising opportunities over competitors including pharmacokinetics adapted to the pathological context.

Latest News

Leadartis to present at BioSpain 2016 in Bilbao
25-08-2016

Leadartis will participate in BioSpain 2016 to be held...

LeadArtis discloses the IMAB project funded by the CDTI´s Excellence initiative
04-09-2016

LeadArtis announces the initiation of the IMAB project (Cancer immunotherapy with bispecific...

LeadArtis leads the cancer immunotherapy with bispecific costimulatory antibodies (IBIMAB) project
02-09-2016

LeadArtis is proud to announce its participation as coordinator of the IBIMAB project (Cancer...